HealThink at 9th Cancer Conference
Cancer is the second leading cause of death after cardiovascular disease, and its incidence in Europe is particularly high in relation to the population, with 3.5 million new diagnoses recorded every year. It is a major challenge for society, but also a major challenge for the sustainability of healthcare systems (source: https://cancerconference.boussiasevents.gr).
HealThink has accumulated extensive experience in oncology / haematology drugs over the last years, and has developed several of tenths of HTA submission dossiers for pharma industry.
We watch closely the Greek environment, and we focus our attention on the innovations that can make the difference to the pathway of the patients. In this context, we have also recognized very early the value of RWD in health sector and designed and run many RWE projects.
We watch closely the Greek environment, and we focus our attention on the innovations that can make the difference to the pathway of the patients. In this context, we have also recognized very early the value of RWD in health sector and designed and run many RWE projects.
So, we are very glad to support and participate in the 9th Cancer Conference, organized by Boussias on September 24th.
The Medical, Value & Access Lead of HealThink, Kelly Avgitidou, will share our experience and present “Oncology Drugs: Advancements, Evaluation and Access”.
We will be happy to meet you and discuss the needs of patients and the priorities of pharma industry.